LAS VEGAS, Jan. 7, 2026 /PRNewswire/ — At CES 2026, a live robotic tactile interaction demonstration at the ENTERPRISE AI Zone in the North Hall drew industry expertsLAS VEGAS, Jan. 7, 2026 /PRNewswire/ — At CES 2026, a live robotic tactile interaction demonstration at the ENTERPRISE AI Zone in the North Hall drew industry experts

PaXini Unveils the “Tactile Infrastructure” for Embodied AI, Redefining Full-Stack Product Matrix at CES 2026

LAS VEGAS, Jan. 7, 2026 /PRNewswire/ — At CES 2026, a live robotic tactile interaction demonstration at the ENTERPRISE AI Zone in the North Hall drew industry experts and media.

Through a complete ice-cream making process—including lever manipulation, ingredient handling, and cup handover—the humanoid robot TORA-ONE showcased its autonomous task-execution capabilities. 

As a leader in high-precision tactile perception and full-stack embodied AI solutions, PaXini presented its comprehensive product matrix to CES 2026. The exhibit featured full-body 6-axis F/T sensing ecosystems, multidimensional tactile dexterous hands, humanoid robots, and an omni-modality data acquisition system.

From Fingertips to Full Body: Endowing Robots with Tactile Sensation

At the core of the robot’s dexterous manipulation is precise perception, which is underpinned by a full-body 6-axis F/T sensing ecosystem. The PX-6AX-GEN3 multidimensional tactile sensor is pivotal for hand perception. It spans three product series and 12 models, achieves <0.5%FS repeatability across the full measurement range, and simultaneously measures 15 sensing dimensions, including six-axis force, material texture, and elastic response.

In addition to comprehensive tactile sensing at the fingertips, force control at the wrist and joints is equally vital. PaXini showcased the PX6D/PXTS, the world’s first commercial Hall-effect 6D force/torque sensor designed for embodied AI, combining extreme lightweight design with advanced on-sensor intelligence. It leads the industry in measurement performance and dynamic response, further enabling precise whole-body force perception and stable force control at a disruptive cost-performance ratio.

From Perception to Embodied AI Execution: The Multidimensional Tactile Dexterous Hand

Translating perception into precise action is the DexH13 multidimensional tactile dexterous hand. Equipped with 1,140 ITPU multidimensional tactile processing units, the DexH13 was able to accurately mirror a wide range of human hand gestures, while demonstrating stable grasping of irregular objects—from test tubes to cubes—and performing delicate tasks like knob turning.

The Ultimate Embodied AI Vehicle: Multidimensional Tactile Humanoid Robots

As the culmination of perception and execution, PaXini’s humanoid robots offer generalization capability and practical performance, unlocking the true value of technological services in industrial applications. The core of these smooth interactions is the deep integration of tactile feedback into motion control: TORA-ONE demonstrated human-like manipulation, including cup receiving, dispensing, and wafer pick-and-place, while TORA-DOUBLE ONE showcased advanced motion control and interaction capabilities, completing complex obstacle-crossing tasks and engaging with visitors through handshakes.

The Fuel for Embodied AI: The World’s First Omni-Modality Embodied AI Data Acquisition System

A major highlight was the exact replica of PaXini’s Omni-Modality Embodied AI Data Acquisition System at the CES venue.

In response to the scarcity of physical contact modality data, PaXini unveiled its pioneering “human-centric” omni-modality data acquisition solution, which significantly improves data acquisition efficiency compared to teleoperation and, being based on human configuration, offers high data reusability and long-term value.

PaXini has established the capacity for large-scale production of nearly 200 million omni-modality data entries annually and plans to open this resource globally via a cloud store, addressing the industry’s “data anxiety” through data infrastructure.

Ecosystem Strategy: Enabling Global Embodied AI Advancement

Through this closed loop of “Tactile Sensors – Robot Platform – Embodied Data – Scenario Application,” PaXini goes beyond showcasing isolated technologies at CES 2026, delivering a complete embodied AI infrastructure. PaXini is dedicated to enabling AI to truly understand the physical world and making intelligent touch accessible everywhere.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/paxini-unveils-the-tactile-infrastructure-for-embodied-ai-redefining-full-stack-product-matrix-at-ces-2026-302655238.html

SOURCE PaXini Tech

Market Opportunity
null Logo
null Price(null)
--
----
USD
null (null) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26